CD274 and neoplasm: In general, hot tumors present higher response rates to immunotherapeutic drugs, such as those targeting programmed death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) [32], which mediate co-inhibitory signals to T-cell activation, resulting in the attenuation of the host immune response to tumor cells [33].